 Vancouver, British Columbia--Newsfile Corp. - June 23, 2020 - FSD Pharma Inc. NASDAQ: HUGE CSE: HUGE FSE: 0K9, a specialty, biotech pharmaceutical RD; company, focused on developing, over time, multiple applications of its lead compound FSD201, has announced favorable topline results from its Phase I first-in-human safety and tolerability study of ultra-micronized palmitolylethanolamide or PEA. This randomized, double-blind, placebo-controlled study of PEA, or FSD201, was conducted at the Alfred Hospital, part of the ... 